Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Spyre Therapeutics, Inc. - Common Stock
(NQ:
SYRE
)
99.61
+4.09 (+4.29%)
Delayed Quote
Updated: 2:25 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Spyre Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
October 18, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
October 05, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
October 05, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
September 08, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
September 03, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
August 25, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
June 15, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
June 03, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 26, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 05, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 16, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 14, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 13, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
April 10, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
March 16, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 19, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
February 18, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
January 12, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 04, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
November 04, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
October 29, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
October 24, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
October 15, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
October 13, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
October 13, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
